Success Metrics

Active Trials
2(33%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
3
50%
Ph phase_3
2
33%

Phase Distribution

3

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Other(2)

Detailed Status

Recruiting2
Not yet recruiting2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 32 (33.3%)

Trials by Status

recruiting233%
not_yet_recruiting233%
unknown233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

NCT07241936
not_yet_recruitingphase_1

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

NCT06577376
recruitingphase_3

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

NCT06313086
not_yet_recruitingphase_3

DP303c in Patients With HER2-positive Advanced Breast Cancer

NCT05901935
unknownphase_1

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

NCT05810103
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07241936Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Recruiting
NCT06577376Phase 1

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Not Yet Recruiting
NCT06313086Phase 3

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Recruiting
NCT05901935Phase 3

DP303c in Patients With HER2-positive Advanced Breast Cancer

Not Yet Recruiting
NCT05810103Phase 1

A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

Unknown
NCT05334810Phase 2

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6